Reports
Status | Drug name | NICE TAs | Comments |
---|---|---|---|
![]() |
Clofarabine injection |
For hospital use only |
|
![]() |
Clomifene tablets |
Specialist recommendation - ovulation induction |
|
![]() |
Clomipramine capsules |
Specialist initiation only |
|
![]() |
Clonazepam injection |
MHRA Category 2: the need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history |
|
![]() |
Clonazepam tablets |
MHRA Category 2: the need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history |
|
![]() |
Clonidine injection |
Hospital use only |
|
![]() |
Clotrimazole 1% solution |
Only with positive culture/sensitivity data |
|
![]() |
Clozapine tablets |
Only for emergency use in existing patients when inpatient at UHB |
|
![]() |
Co-amilofruse tablets |
Combination products should be avoided, unless compliance is an issue |
|
![]() |
Co-codamol 30/500 capsules |
Wherever possible, avoid theu se of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine/dihydrocodeine are deemed products less suitable for prescribing in the BNF. Capsules have a very high relative cost. Sodium content. Only if swallowing difficulties. |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- Next page
- Last page